Invitrogen s New CMO Defines Firm s Patient-Centric View | GenomeWeb

David Onions was recently promoted from the role of chief scientific officer of Invitrogen unit BioReliance to chief medical officer of Invitrogen. The position is a new one at Invitrogen and a seemingly unusual role for someone at a firm focused on developing and selling molecular biology tools. This week, Onions spoke with BioCommerce Week about his new position and Invitrogen's strategy for more collaborative efforts in medical research that are closer to the patient.

Why does Invitrogen need a chief medical officer?

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."